Veru Inc. (VERU) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Veru Inc (VERU) by buying shares or fractional shares at any major US broker, through a small-cap biotech ETF that happens to hold it, or as one speculative holding in a thematic basket. Veru is a small clinical-stage biopharmaceutical company on the Nasdaq that has pivoted toward cardiometabolic and obesity medicine. Its lead program is enobosarm, an oral selective androgen receptor modulator being studied to preserve muscle and physical function while augmenting fat loss when combined with GLP-1 weight-loss drugs like semaglutide and tirzepatide. The core thesis is a single high-risk, high-reward bet: that enobosarm's Phase 2b PLATEAU trial succeeds and positions Veru inside the enormous GLP-1 obesity market. Until then it has no approved cardiometabolic product and burns cash.
VERU stock price
As of 2026-07-14, Veru Inc. (VERU) last closed at $2.35, down 60.9% over the past year. Over the past 52 weeks it has traded between $2.09 and $6.10.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Veru Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Veru Inc. (VERU) do?
Veru Inc is a small biopharmaceutical company that has repositioned itself around cardiometabolic and obesity disease after earlier chapters in oncology and men's health. Its drug development program now centers on two small molecules: enobosarm and sabizabulin. Enobosarm is the lead asset, an oral selective androgen receptor modulator being developed to preserve lean muscle mass and physical function while enhancing fat and weight loss when used alongside GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide. The strategic logic is that GLP-1 drugs drive large weight loss but also strip away muscle, and a therapy that protects muscle quality could ride alongside one of the fastest-growing drug categories in the world. In September 2025 Veru reported an FDA meeting that clarified the regulatory path, and in March 2026 it enrolled the first patient in its Phase 2b PLATEAU trial of enobosarm plus semaglutide, focused on older, higher-BMI patients.
The financial picture in mid-2026 is that of an early-stage biotech living trial-to-trial. As of March 31, 2026 the company reported roughly $27.6 million in cash, cash equivalents, and restricted cash, up from about $15.8 million six months earlier, helped by proceeds from selling its legacy FC2 female condom business and by an underwritten stock-and-warrant offering. Its fiscal Q2 2026 net loss narrowed to about $2.7 million from $7.9 million a year earlier, but its quarterly filings carried a going-concern warning and flagged the need for additional funding. Interim DXA-based data from PLATEAU is expected in early 2027 with topline data in late 2027, so the stock is likely to trade on trial news, financing announcements, and dilution rather than on revenue for the foreseeable future.
What's driving Veru Inc. (VERU)?
1. Enobosarm in the GLP-1 muscle-preservation opportunity
Veru's central thrust is positioning enobosarm as a companion to GLP-1 weight-loss drugs. GLP-1 therapies produce large weight loss but also meaningful muscle loss, and Veru is testing whether enobosarm can preserve lean mass and physical function while still allowing fat loss. If the Phase 2b PLATEAU trial validates that hypothesis, enobosarm could target one of the largest and fastest-growing drug markets. This is the reason the stock exists in its current form, and the entire thesis leans on it.
2. Regulatory clarity from the FDA
In September 2025 Veru reported a successful FDA meeting that gave a defined path: incremental placebo-corrected weight loss of at least 5% at 52 weeks of maintenance could support approval, and smaller incremental weight loss paired with a clinically meaningful benefit such as preserved physical function may also be approvable. Having an agreed endpoint framework reduces one layer of uncertainty, though it does not guarantee the trial hits those bars.
3. Portfolio simplification and cash extension
Veru has been shedding legacy operations to concentrate on its cardiometabolic pipeline, including selling its FC2 female condom business for gross proceeds of about $16.3 million and divesting other assets. Combined with an equity raise, these moves lifted cash to roughly $27.6 million at March 31, 2026 and narrowed the operating loss. Simplifying to a focused clinical-stage story can make the pipeline easier to fund and to value, but it also removes revenue that once offset the burn.
4. Sabizabulin and pipeline optionality
Beyond enobosarm, Veru retains sabizabulin, a second small-molecule asset, giving it some pipeline optionality if the lead program stumbles or if new indications emerge. A secondary program can matter for a single-asset-heavy biotech because it offers a fallback and potential partnering value. In practice, though, investor attention and the company's resources are concentrated on enobosarm, so sabizabulin is a smaller part of the current story.
What are the risks to Veru Inc. (VERU)?
The dominant risk is clinical and binary: Veru is a small clinical-stage biotech with no approved cardiometabolic product, so a failed, delayed, or ambiguous PLATEAU readout could sharply reduce the value of the entire thesis. Financing risk is close behind. The company reported roughly $27.6 million in cash at March 31, 2026 and its filings carried a going-concern warning, meaning it will likely need to raise more money, and past raises have diluted existing shareholders through stock and warrant offerings. As a micro-cap, the shares can be thinly traded and highly volatile, moving sharply on trial updates, financing news, and even mechanics like antidilution provisions. There is also competitive risk, since large pharmaceutical companies are pursuing their own muscle-preservation and next-generation obesity approaches. Any investor should treat VERU as a speculative position sized accordingly, and none of this is investment advice.
How is Veru Inc. (VERU) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Veru Inc.'s investor relations page or your broker.
- Stage: Clinical-stage biopharma with no approved cardiometabolic product; results driven by trials, not product revenue
- Cash position: ~$27.6 million cash, cash equivalents, and restricted cash as of March 31, 2026 (up from ~$15.8 million six months earlier)
- Profitability: Loss-making; fiscal Q2 2026 net loss narrowed to ~$2.7 million from ~$7.9 million a year earlier
- Going concern: Filings carried a going-concern warning and flagged the need for additional funding
- Dilution: History of raising cash via stock and warrant offerings, which dilutes existing shareholders
- Valuation lens: No meaningful P/E (no earnings); valued on pipeline probability, cash runway, and trial catalysts rather than multiples
Figures are approximate and tied to the asOf date; verify live numbers before acting. For a clinical-stage biotech like Veru, traditional earnings multiples do not apply because there are no meaningful earnings, so the market prices the probability that enobosarm succeeds against the cash needed to get there. Key dates to watch are the PLATEAU interim DXA data expected in early 2027 and topline data in late 2027, plus any financing that extends the runway but adds shares.
Who competes with Veru Inc. (VERU)?
Large GLP-1 and obesity leaders
Eli Lilly and Novo Nordisk dominate the GLP-1 weight-loss market with tirzepatide and semaglutide. Veru is not a direct rival to them; it is trying to ride alongside their drugs by preserving muscle. But these giants are also developing their own muscle-preservation and next-generation obesity approaches, which is both an opportunity (partnering) and a competitive threat to Veru's niche.
Muscle-preservation and cardiometabolic biotechs
Other companies pursuing muscle preservation, myostatin pathways, or body-composition drugs alongside GLP-1s, such as Regeneron, Scholar Rock, and BioAge-type players, compete for the same thesis that weight loss should protect lean mass. Veru's differentiation is an oral selective androgen receptor modulator, but rival mechanisms could reach the market with more resources behind them.
Small clinical-stage biopharma peers
As a micro-cap, single-catalyst biotech, Veru trades in the same speculative bucket as many other pre-approval clinical-stage companies. These names compete less on products than for investor capital and attention, and they share the same profile of binary trial risk, cash-runway dependence, and dilution. Broad small-cap biotech ETFs offer a diversified alternative to owning any one of them.
How to invest in Veru Inc. (VERU)
There are three common ways to get VERU exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so VERU sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where VERU fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Veru Inc. (VERU)
Veru is a speculative, clinical-stage biotech whose value hinges almost entirely on whether enobosarm proves it can preserve muscle for GLP-1 patients. It has a small cash balance, a going-concern flag, and a history of dilution, so it rewards a positive trial readout and punishes delay. This is a binary, high-risk name, not a stable holding.
Build a basket around VERU with Walnut
Use Veru Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is VERU a good stock to buy right now?
+
That depends entirely on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that enobosarm could preserve muscle for the huge and growing population on GLP-1 weight-loss drugs, with a defined FDA path and a Phase 2b trial underway. The bear case is that Veru is a speculative clinical-stage biotech with no approved cardiometabolic product, a small cash balance, a going-concern warning, and a history of dilution, so a poor trial result could hit the shares hard. Weigh both against your portfolio and how much risk you can absorb.
What does Veru actually do?
+
Veru is a small clinical-stage biopharmaceutical company focused on cardiometabolic and obesity disease. Its lead drug, enobosarm, is an oral selective androgen receptor modulator being studied to preserve muscle and physical function while enhancing fat loss in people taking GLP-1 weight-loss drugs. It also has a second molecule, sabizabulin. It does not yet sell an approved cardiometabolic product, so its results are driven by clinical trials rather than revenue.
What is enobosarm and why does it matter?
+
Enobosarm is Veru's lead drug candidate, an oral selective androgen receptor modulator. GLP-1 weight-loss drugs cause large weight loss but also strip away muscle, and enobosarm is being tested to preserve lean muscle and physical function while still allowing fat loss when combined with drugs like semaglutide and tirzepatide. It matters because success could plug Veru into one of the largest drug markets in medicine, though that outcome is far from certain.
What is the PLATEAU trial?
+
PLATEAU is Veru's Phase 2b clinical trial testing enobosarm alongside semaglutide, with a focus on older patients (65 and up) and those with higher BMI who have the most weight to lose. The company enrolled its first patient in March 2026. Interim DXA-based body-composition data is expected in early 2027 and topline results in late 2027, making those readouts the key catalysts for the stock.
Is Veru profitable?
+
No. Veru is a clinical-stage biotech that loses money as it funds research and trials. Its fiscal Q2 2026 net loss narrowed to about $2.7 million from about $7.9 million a year earlier, helped by cost cuts and divestitures, but it still operates at a loss. Because it has no meaningful earnings, standard price-to-earnings valuation does not apply to the stock.
How much cash does Veru have and will it need to raise more?
+
As of March 31, 2026 Veru reported roughly $27.6 million in cash, cash equivalents, and restricted cash, up from about $15.8 million six months earlier after asset sales and an equity offering. However, its filings carried a going-concern warning and flagged a need for additional funding, so further capital raises are likely. Those raises have historically diluted existing shareholders.
Why is VERU stock so volatile?
+
Veru is a micro-cap, single-catalyst biotech whose value hinges on one lead program. That makes the shares highly sensitive to trial updates, FDA news, financing announcements, and even mechanical factors like warrant antidilution provisions. Thin trading volume can amplify moves in both directions. This binary, news-driven profile is typical of small clinical-stage biotech names and is a key reason the stock can swing sharply.
Does Veru pay a dividend?
+
No. As a loss-making clinical-stage biotech that needs its cash to fund trials and operations, Veru does not pay a dividend and is very unlikely to while it remains pre-approval. Investors in a name like this are betting on clinical and eventual commercial success, not on income. Always confirm the latest company disclosures before assuming any capital return.
How can I get exposure to Veru through an ETF?
+
VERU may appear in some broad small-cap or biotech ETFs, though as a micro-cap its weighting in any fund is typically tiny. ETF exposure spreads single-stock risk across many holdings but dilutes how much a Veru move affects you. If you want meaningful exposure to this specific thesis you would generally need to hold the shares directly, sized to reflect the high risk.
What are the main risks of investing in VERU?
+
The biggest risk is binary trial risk: a failed, delayed, or ambiguous PLATEAU readout could sharply cut the value of the whole thesis, since Veru has no approved cardiometabolic product. Financing risk is close behind, given a small cash balance, a going-concern warning, and a track record of dilutive raises. Add competition from far larger pharma companies pursuing their own obesity and muscle-preservation drugs, plus micro-cap volatility and thin liquidity.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Veru Inc.'s investor relations page or your broker before making investment decisions.